Total Payments
$2,948
2019 Payments
$1,590
Companies
6
Transactions
16
Payment Breakdown by Category
Travel$1,618 (54.9%)
Food & Beverage$840.09 (28.5%)
Research$482.52 (16.4%)
Education$7.12 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $1,618 | 5 | 54.9% |
| Food and Beverage | $840.09 | 7 | 28.5% |
| Unspecified | $482.52 | 3 | 16.4% |
| Education | $7.12 | 1 | 0.2% |
Payments by Type
General
$2,465
13 transactions
Research
$482.52
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $2,385 | 7 | $0 (2019) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $482.52 | 3 | $0 (2019) |
| Alkermes, Inc. | $32.68 | 2 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $19.77 | 2 | $0 (2018) |
| Takeda Pharmaceuticals America, Inc. | $15.08 | 1 | $0 (2017) |
| Otsuka America Pharmaceutical, Inc. | $12.90 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $1,590 | 9 | PFIZER INC. ($1,062) |
| 2018 | $1,343 | 6 | PFIZER INC. ($1,323) |
| 2017 | $15.08 | 1 | Takeda Pharmaceuticals America, Inc. ($15.08) |
All Payment Transactions
16 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/25/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $312.52 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER • Category: PSYCHIATRY | ||||||
| 07/25/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER • Category: PSYCHIATRY | ||||||
| 07/24/2019 | Otsuka Pharmaceutical Development & Commercialization, Inc. | REXULTI (Drug) | — | In-kind items and services | $120.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER • Category: PSYCHIATRY | ||||||
| 05/02/2019 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $12.90 | General |
| Category: PSYCHIATRY | ||||||
| 03/25/2019 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: CNS | ||||||
| 03/11/2019 | PFIZER INC. | GEODON (Drug) | Food and Beverage | In-kind items and services | $441.76 | General |
| Category: NEUROSCIENCE | ||||||
| 03/11/2019 | PFIZER INC. | GEODON (Drug) | Travel and Lodging | In-kind items and services | $430.88 | General |
| Category: NEUROSCIENCE | ||||||
| 03/11/2019 | PFIZER INC. | GEODON (Drug) | Travel and Lodging | In-kind items and services | $189.00 | General |
| Category: NEUROSCIENCE | ||||||
| 01/15/2019 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: CNS | ||||||
| 12/14/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $12.65 | General |
| Category: Central Nervous System (CNS) | ||||||
| 11/12/2018 | Takeda Pharmaceuticals U.S.A., Inc. | Trintellix (Drug) | Education | In-kind items and services | $7.12 | General |
| Category: Central Nervous System (CNS) | ||||||
| 01/11/2018 | PFIZER INC. | QUILLICHEW ER (Drug) | Travel and Lodging | In-kind items and services | $485.40 | General |
| Category: NEUROSCIENCE | ||||||
| 01/11/2018 | PFIZER INC. | QUILLICHEW ER (Drug) | Travel and Lodging | In-kind items and services | $380.26 | General |
| Category: NEUROSCIENCE | ||||||
| 01/11/2018 | PFIZER INC. | QUILLICHEW ER (Drug) | Food and Beverage | In-kind items and services | $325.02 | General |
| Category: NEUROSCIENCE | ||||||
| 01/11/2018 | PFIZER INC. | QUILLICHEW ER (Drug) | Travel and Lodging | In-kind items and services | $132.45 | General |
| Category: NEUROSCIENCE | ||||||
| 08/17/2017 | Takeda Pharmaceuticals America, Inc. | Trintellix (Drug) | Food and Beverage | In-kind items and services | $15.08 | General |
| Category: Central Nervous System (CNS) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF BREXPIPRAZOLE IN TREATMENT OF CHILDREN AND ADOLESCENTS WITH IRRITABILITY ASSOCIATED WITH AUTISM SPECTRUM DISORDER | Otsuka Pharmaceutical Development & Commercialization, Inc. | $482.52 | 3 |
About Dr. Ashraf Attalla, MD
Dr. Ashraf Attalla, MD is a Child & Adolescent Psychiatry healthcare provider based in Smyrna, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1417067489.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ashraf Attalla, MD has received a total of $2,948 in payments from pharmaceutical and medical device companies, with $1,590 received in 2019. These payments were reported across 16 transactions from 6 companies. The most common payment nature is "Travel and Lodging" ($1,618).
Ad
Practice Information
- Specialty Child & Adolescent Psychiatry
- Other Specialties Psychiatry
- Location Smyrna, GA
- Active Since 08/30/2006
- Last Updated 03/23/2017
- Taxonomy Code 2084P0804X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1417067489
Products in Payments
- QUILLICHEW ER (Drug) $1,323
- GEODON (Drug) $1,062
- REXULTI (Drug) $495.42
- Trintellix (Drug) $34.85
- ARISTADA (Drug) $32.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Child & Adolescent Psychiatry Doctors in Smyrna
Dr. Munjal Shroff, Do, DO
Child & Adolescent Psychiatry — Payments: $302,692
Child & Adolescent Psychiatry $302,692
Dr. Arun Munjal, M.d, M.D
Child & Adolescent Psychiatry — Payments: $10,837
Child & Adolescent Psychiatry $10,837
Theodore Morgan, Md, MD
Child & Adolescent Psychiatry — Payments: $8,931
Child & Adolescent Psychiatry $8,931